Back to Conference page
The 13th World Conference on Tobacco OR Health
Building capacity for a tobacco-free world
July 12-15, 2006, Washington, DC, USA
Objective: To evaluate outcomes of smoking cessation with bupropion, as single terapeutical alternative in smoking cessation.
Methods: Patients undergoing bupropion terapy for 2 months and called in follow-up for 6 months were reviewed.
Number of packs/year, nicotine dependency scores. previous quit attempts, coexistent alcoholism or depressive symptoms and smoking associated diseases were annalysed.
In follow-up we registered withdrawal symptoms, side effects of bupropion and monitored abstinence by measuring carbon monoxide in the exhaled air.
Results: 68 patients (42 M, 26 F), of mean age 38 years, heavily addicted to nicotine( Fagerstrom/7+- 2), were prescribed bupropion for 8 weeks. 62.3% had previously tried to quit smoking and 7% had already failed with bupropion. 24% admitted alcohol concomitent abuse, 22% depression history, 20% had also COPD and 14.6% cardiovascular involvement.
The treatment was completely achieved in 64%. Drop-outs were related to withdrawal syndrome ( 28%) and headaches(46.8%).No patient in the second bupropion terapy cure has discontinued treatment.
Succes rate was: continuous abstinence in 28% and smoking reduction in 14.2%.
Conclusions: Outcome of bupropion terapy was encouraging, but under our expectancies, considering the unique pharmacological terapeutical alternative bupropion represents now in Romania.